Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia

Study Overview
=================
Brief Summary
-----------------
Phase 3 study to evaluate the safety and effectiveness of LNZ101 for the treatment of Presbyopia.

Detailed Description
-----------------
Phase 3 study to evaluate the safety and effectiveness of LNZ101 compared with LNZ100 and Brimonidine for the treatment of Presbyopia.

Official Title
-----------------
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia

Conditions
-----------------
Presbyopia, Refractive Error, Near Vision, Miosis, Eye Diseases

Intervention / Treatment
-----------------
* Drug: Aceclidine + Brimonidine
* Drug: Aceclidine
* Drug: Brimonidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed; Be able and willing to follow all instructions and attend all study visits; Be 45-75 years of age of either sex and any race or ethnicity at Visit 1; Have +1.00 to -4.00 diopter (D) of sphere calculated in minus cylinder (so that spherical equivalent (SE) results in myopia no more severe than -4.00 D MRSE) in both eyes determined by manifest refraction documented at Visit 1; Have ≤2.00 D of cylinder (minus cylinder) in both eyes determined by manifest refraction documented at Visit 1; Be presbyopic as determined at Visit 1 Exclusion Criteria: Subjects must not: Be a female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy; Have known contraindications or sensitivity to the use of any of the study medications or their components; Have an active ocular infection at Visit 1 or at Visit 2 (bacterial, viral, or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation in either eye; Have moderate or severe dry eye defined as total central corneal fluorescein staining in either eye at Visit 1; Have clinically significant abnormal lens findings including early lens changes in either eye during dilated slit-lamp biomicroscopy and fundus exam documented within 3 months of Visit 1 or at Visit 1;

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: A multi-center, double-masked, randomized, active-controlled, safety and efficacy study
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Aceclidine + Brimonidine (LNZ101) dosed bilaterally<br>LNZ101 (Aceclidine /Brimonidine) ophthalmic solution | Drug: Aceclidine + Brimonidine<br>* LNZ101 (Aceclidine/Brimonidine) ophthalmic solution<br>|
| Experimental: Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally<br>LNZ100 (Aceclidine) ophthalmic solution | Drug: Aceclidine<br>* LNZ100 Aceclidine ophthalmic solution<br>|
| Experimental: Brimonidine ophthalmic solution dosed bilaterally<br>Brimonidine ophthalmic solution | Drug: Brimonidine<br>* Brimonidine ophthalmic solution<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Outcome | Efficacy Study of the percentage of subjects who achieve a 3-line or greater improvement from baseline in the study eye with no loss in BCDVA ≥ 5 letters (ETDRS chart at 4 m). | 3 hours post-treatment in the study eye | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmaceutical Solutions, Eye Drops, CLARITY, Presbyopia, Ophthalmic Solutions, Miotic